# US 2026/0297134 A1 · Cyclic peptides as pet imaging agents of granzyme b

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297134 A1
- Document ID: US20260297134A1
- Status: Published application
- Kind: A1
- Application number: 19/479,468
- Filed: 2024-04-29
- Published: 2026-10-01
- Earliest claimed: 2023-05-03
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme LLC
- Inventors: Idriss Bennacef; Tapan K. Nayak; Jeffrey William Schubert; William D. Shipe; David M. Tellers; Federica Orvieto; Valerio Piacenti
- Web page: https://patentgrep.com/patent/US20260297134A1

## CPC

- C07K 7/64: Cyclic peptides containing only normal peptide links
- A61K 51/08: Peptides, e.g. proteins {, carriers being peptides, polyamino acids, proteins}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are cyclic peptides, their salts, pharmaceutical compositions comprising them, diagnostic and therapeutic uses and processes for making such compounds, which bind to granzyme B and may be suitable for imaging granzyme B. Further provided are compounds useful as a radiotracer for positron emission tomography (PET) and/or single photon emission tomography (SPECT) imaging. The use of the compounds as imaging agents of granzyme B is further disclosed.

## Claims

### Claim 1

A macrocyclic peptide of Formula I:
and pharmaceutically acceptable salts thereof, wherein:
R1 and R2 are each independently selected from hydrogen, C1-6 alkyl and C6-10 aryl, said aryl optionally substituted with 1 to 3 groups selected from C1-6 alkyl, halogen, and hydroxyl;
R3 is hydrogen or CH3;
R4, R6, R7, and R12 are each independently selected from C1-6 alkyl, and —CH2-aryl optionally substituted with 1 to 3 substituents selected from hydroxy, C1-6 alkyl and halogen,
R8, R9, R10, and R11 are each independently hydrogen or C1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups selected from Ra;
Ra is selected from hydroxyl, —COOH, —NH2, —NHC(═NH2)NI-2 and C(O)NH2;
R13 is selected from C3-10heteroaryl and hydrogen, said heteroaryl optionally substituted with 1 to 3 groups selected from OH, C1-6 alkyl and halogen;
R14 is selected from —NH2, —CH2NH2
wherein R15 is selected from
(i) H;
(ii)
(iii) R0aC(O)— wherein R0a is C1-3 alkyl, or a polyethylene glycol polymer; and a chelating moiety, optionally having a positron emitting isotope as an imaging agent.

### Claim 2 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is selected from C1-6 alkyl and phenyl, said alkyl and phenyl optionally substituted with 1 to 3 groups selected from C1-6 alkyl, halogen, and hydroxyl.

### Claim 3 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein each of R4, R6, R7, and R12 are independently selected from C1-6 alkyl, and (CH2)phenyl, wherein said alkyl and phenyl are optionally substituted with 1 to 3 groups selected from C1-6 alkyl, halogen, and hydroxyl.

### Claim 4 (depends on 3)

The macrocyclic peptide according to claim 3, or a pharmaceutically acceptable salt thereof, wherein R6, R7, and R12 are each (CH2)phenyl, said phenyl optionally substituted with 1 to 3 groups selected from C1-6 alkyl, halogen, and hydroxyl.

### Claim 5 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R8, R9, R10 and R11, are each C1-6 alkyl, said alkyl optionally substituted with 1 to 3 Ra.

### Claim 6 (depends on 5)

The macrocyclic peptide according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R8, R10 and R11, are independently selected from methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl, said methyl, ethyl, propyl, isopropyl, butyl, pentyl, and hexyl optionally substituted with 1 to 3 groups selected from R.

### Claim 7 (depends on 5)

The macrocyclic peptide according to claim 5, or a pharmaceutically acceptable salt thereof, wherein R8, R10, and R11 are each optionally substituted isopropyl.

### Claim 8 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R9 is C1-6 alkyl, said alkyl optionally substituted with 1 to 3 Ra.

### Claim 9 (depends on 8)

The macrocyclic peptide according to claim 8, or a pharmaceutically acceptable salt thereof, wherein R9 is a methylene substituted with C(O)OH.

### Claim 10 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein one of R2 and R4 is C1-6 alkyl and the other is C6-10 aryl or CH2C6-10 aryl, said aryl optionally substituted with 1 to 3 groups selected from C1-6 alkyl, halogen, and hydroxyl.

### Claim 11 (depends on 10)

The macrocyclic peptide according to claim 10, or a pharmaceutically acceptable salt thereof, wherein each of R2 and R4 is phenyl or CH2phenyl, optionally substituted with 1 to 3 groups selected from C1-6 alkyl, fluorine and hydroxyl.

### Claim 12 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R13 is hydrogen.

### Claim 13 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R13 is C3-10heteroaryl, said heteroaryl optionally substituted with 1 to 3 groups selected from OH, C1-6 alkyl and halogen;

### Claim 14 (depends on 13)

The macrocyclic peptide according to claim 13, or a pharmaceutically acceptable salt thereof, wherein R13 is optionally substituted imidazolyl.

### Claim 15 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R14 is NH2.

### Claim 16 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt Thereof, wherein R14 is

### Claim 17 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R14 is

### Claim 18 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R14 is

### Claim 19 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R14 is

### Claim 20 (depends on 19)

The macrocyclic peptide according to claim 19, or a pharmaceutically acceptable salt thereof, wherein R15 is independently selected from hydrogen and R0aC(O)— wherein R0a is C1-3 alkyl, or a polyethylene glycol polymer selected from PEG 1-24.

### Claim 21 (depends on 19)

The macrocyclic peptide according to claim 19 or a pharmaceutically acceptable salt thereof, wherein R15 is a chelating moiety independently selected from desferrioxamine; 1, 4, 7, 10-tetraacetic acid; diethylenetriaminepenaacetic acid; ethylenediaminetetraacetic acid; (1, 4, 7, 10-Tetraazacyclododecane-1, 4, 7, 10-tetra(methylene phosphonic) acid; (1R, 4R, 7R, 10R)-α′α″α′″-tetramethyl-1, 4, 7, 10-tetraazacyclododecane 1, 4, 7, 10-tetraacetic acid; 1, 4, 8, 11-Tetraazacyclotetradecane-1, 4, 8, 11-tetraacetic acid; H4octapa, H6phospa, H2dedpa, H5decapa, H2azapa; HOPO; DO2 Å; 1, 4, 7, 10-Tetrakis(carbamoylmethyl)-1, 4, 7, 10-tetraazacyclododecane; 1, 4, 7-triazacyclononane-N, N′,N″-triacetic acid; 1, 4, 8, 11-tetraazabicyclo[6.6.2]hexadecane-4, 11-dicetic acid; 1, 4, 7, 10-Tetraazacyclododecane; 1, 4, 8, 11-tetraazacyclotetradecane, octadentate chelator, hexadentate chelator, phosphonate-based chelator, macrocyclic chelator, chelators comprising macrocyclic terephthalamide ligands, bifunctional chelator, fusarinine C and fusarinine C derivative chelator, triacetylfusarinine C, ferrioxamine E, ferrioxamine B, and ferrichrome A, said chelating moiety optionally having a positron emitting isotope as an imaging agent.

### Claim 22 (depends on 19)

The macrocyclic peptide according to claim 19, or a pharmaceutically acceptable salt thereof, wherein R15 is selected from
wherein (ii) is optionally chelated to a positron emitting isotope.

### Claim 23 (depends on 22)

The macrocyclic peptide or a pharmaceutically acceptable salt thereof according to claim 22 wherein the positron emitting isotope is selected from 67Ga, 68Ga, 18F, 64Cu, 111In and 18F—Al.

### Claim 24 (depends on 1)

The macrocyclic peptide or a pharmaceutically acceptable salt thereof according to claim 1, which comprises a chelating moiety.

### Claim 25 (depends on 24)

The macrocyclic peptide or a pharmaceutically acceptable salt thereof according to claim 24 wherein the chelating moiety comprises a positron emitting isotope is selected from 68Ga, 18F, and 64Cu.

### Claim 26 (depends on 1)

The macrocyclic peptide according to claim 1, or a pharmaceutically acceptable salt thereof, represented by structural Formula I′:
said Formula I′ optionally containing 1 or more positron emitting imaging agents.

### Claim 27

A compound or pharmaceutically acceptable salt thereof, selected from
Compd
#
Linear Peptide Sequence
1
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 8)
2
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K-NH2 (SEQ ID NO:
9)
3
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(NOTA)-NH2 (SEQ
ID NO: 34)
4
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(Prop)-NH2 (SEQ ID
NO: 35)
5
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(68Ga-NOTA)-NH2
(SEQ ID NO: 36)
6
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(18F-AlF-NOTA)-
NH2 (SEQ ID NO: 37)
7
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.C.G.G.K(18F-AlF-NOTA)-
NH2 (SEQ ID NO: 38)
8
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.C.G.G.K(NOTA)-NH2 (SEQ
ID NO: 39)
9
ClAc.F.NMeF.A.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K-NH2 (SEQ ID NO: 40)
10
ClAc.F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.C.G.K-NH2 (SEQ ID NO: 41)
11
ClAc.F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.C.G.K.K-NH2 (SEQ ID NO:
42)
12
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.K-NH2 (SEQ ID NO: 43)
13
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.K.K-NH2 (SEQ ID NO:
44)
14
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.A.C.G-NH2 (SEQ ID NO: 45)
15
ClAc.F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 46)
16
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 47)
17
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.A.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 48)
18
ClAc.F.NMeF.A.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 49)
19
CIAc.A.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 50)
20
ClAc.F.NMeF.NMeF.Y.Y.D.A.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 51)
21
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.A.NMeF.H.C.G-NH2 (SEQ ID NO: 52)
22
ClAc.F.NMeF.NMeF.Y.Y.D.V.A.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 53)
23
ClAc.F.NMeF.NMeF.A.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 54)
24
ClAc.F.NMeF.NMeA.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 55)
25
ClAc.F.NMeA.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G-NH2 (SEQ ID NO: 16)
26
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(111In-NOTA)-NH2
(SEQ ID NO: 18)
27
ClAc.F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.C.G.G.K(67Ga-NOTA)-NH2
(SEQ ID NO: 10)

### Claim 28 (depends on 1)

A macrocyclic peptide, or pharmaceutically acceptable salt thereof of claim 1, selected from:
Compd #
Macrocyclic Peptide Sequence
1a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 2)
2a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K-NH2 (SEQ ID NO:
3)
3a
*F.NMeF.NmeF.Y.Y.D.V.D.V.D.V.Y.NmeF.H.*C.G.G.K(NOTA)-NH2 (SEQ
ID NO: 4)
4a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K(Prop)-NH2 (SEQ ID
NO: 5)
5a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K(68Ga-NOTA)-NH2
(SEQ ID NO: 6)
6a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K(18F-AIF-NOTA)-
NH2 (SEQ ID NO: 7)
7a
*F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.*C.G.G.K(18F-AIF-NOTA)-
NH2 (SEQ ID NO: 19)
8a
*F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.*C.G.G.K(NOTA)-NH2 (SEQ
ID NO: 17)
9a
*F.NMeF.A.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K-NH2 (SEQ ID NO: 11)
10a
*F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.*C.G.K-NH2 (SEQ ID NO: 12)
11a
*F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.*C.G.K.K-NH2 (SEQ ID NO:
13)
12a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.K-NH2 (SEQ ID NO: 14)
13a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.K.K-NH2 (SEQ ID NO:
15)
14a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.A.*C.G-NH2 (SEQ ID NO: 22)
15a
*F.NMeF.NMeF.Y.A.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 23)
16a
*F.NMeF.NMeF.Y.Y.D.V.D.A.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 24)
17a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.A.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 25)
18a
*F.NMeF.A.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 26)
19a
*A.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 27)
20a
*F.NMeF.NMeF.Y.Y.D.A.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 28)
21a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.A.NMeF.H.*C.G-NH2 (SEQ ID NO: 29)
22a
*F.NMeF.NMeF.Y.Y.D.V.A.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 30)
23a
*F.NMeF.NMeF.A.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 31)
24a
*F.NMeF.NMeA.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 32)
25a
*F.NMeA.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G-NH2 (SEQ ID NO: 33)
26a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K(111In-NOTA)-NH2
(SEQ ID NO: 20)
27a
*F.NMeF.NMeF.Y.Y.D.V.D.V.D.V.Y.NMeF.H.*C.G.G.K(67Ga-NOTA)-NH2
(SEQ ID NO: 21)
wherein * represent point of amino acid linkage between amino acid phenylalanine (F), or alanine (A) and sulfur on amino acid cysteine (C).

### Claim 29 (depends on 1)

The macrocyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, which is a binder of granzyme B.

### Claim 30 (depends on 1)

The macrocyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof, which is an inhibitor of granzyme B.

### Claim 31 (depends on 1)

A method of imaging granzyme B in a cell or tissue comprising contacting the cell or tissue with a of macrocyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof and imaging the cell or tissue with a suitable imaging technique, thereby imaging granzyme B in the cell or tissue.

### Claim 32 (depends on 1)

A method for treating a disease where granzyme B is implicated, comprising administering to a subject in need thereof a macrocyclic peptide of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim at position 33

-34. (canceled)

### Claim 35 (depends on 1)

A pharmaceutical composition comprising a macrocyclic peptide of claim 1, and a pharmaceutically acceptable carrier or excipient.
